{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T16:34:22Z","timestamp":1792946062863,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030610","name":"Emory University Department of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.conctc.2026.101683","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:21:43Z","timestamp":1788996103000},"page":"101683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Progesterone in feminizing gender affirming hormone therapy: study protocol for a randomized placebo-controlled trial"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0898-441X","authenticated-orcid":false,"given":"David R.","family":"Cromer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela S.","family":"Diego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6280-4236","authenticated-orcid":false,"given":"Thomas","family":"Luke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elle","family":"Deppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenmei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6562-1450","authenticated-orcid":false,"given":"Kelly","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7213-6065","authenticated-orcid":false,"given":"Ryan J.","family":"Kann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Nilo G.","family":"Binongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4021-5853","authenticated-orcid":false,"given":"Vin","family":"Tangpricha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2026.101683_bib1","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-Dysphoric\/gender-incongruent persons: an endocrine society* clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.conctc.2026.101683_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of care for the health of transgender and gender diverse people, version 8","volume":"23","author":"Coleman","year":"2022","journal-title":"Int. J. Transgender Health"},{"key":"10.1016\/j.conctc.2026.101683_bib3","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142029","article-title":"Research gaps in medical treatment of transgender\/nonbinary people","volume":"131","author":"Safer","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.conctc.2026.101683_bib4","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.eprac.2025.06.028","article-title":"Progestogen experience among transgender women and gender diverse adults assigned Male at birth in the United States","volume":"31","author":"Chang","year":"2025","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.conctc.2026.101683_bib5","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.eprac.2022.08.012","article-title":"Progestogen use in gender-affirming hormone therapy: a systematic review","volume":"28","author":"Patel","year":"2022","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.conctc.2026.101683_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/trgh.2019.0061","article-title":"An observational study of hypertension and thromboembolism among transgender patients using gender-affirming hormone therapy","volume":"5","author":"Pyra","year":"2020","journal-title":"Transgender Health"},{"key":"10.1016\/j.conctc.2026.101683_bib7","doi-asserted-by":"crossref","DOI":"10.1530\/EC-22-0170","article-title":"Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study","volume":"11","author":"Nolan","year":"2022","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.conctc.2026.101683_bib8","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"l162","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.conctc.2026.101683_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011039","article-title":"Key to life: physiological role and clinical implications of progesterone","volume":"22","author":"Nagy","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.conctc.2026.101683_bib11","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a003178","article-title":"Hormone action in the mammary gland","volume":"2","author":"Brisken","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.conctc.2026.101683_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.yfrne.2007.05.002","article-title":"Regulation of anxiety during the postpartum period","volume":"28","author":"Lonstein","year":"2007","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.conctc.2026.101683_bib13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/15246090050020691","article-title":"Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in Postmenopausal Women: a cross-sectional survey","volume":"9","author":"Fitzpatrick","year":"2000","journal-title":"J. Womens Health Gend. Based Med."},{"key":"10.1016\/j.conctc.2026.101683_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/13697137.2012.666456","article-title":"Hormone therapy and breast cancer risk 10 years after the WHI","volume":"15","author":"Gompel","year":"2012","journal-title":"Climacteric"},{"key":"10.1016\/j.conctc.2026.101683_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084698","article-title":"Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-Month randomized, placebo-controlled trial in healthy early postmenopausal women","volume":"9","author":"Prior","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.conctc.2026.101683_bib16","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.3390\/jcm13226795","article-title":"The potential health risks and benefits of progesterone in the transgender woman population\u2014A narrative review","volume":"13","author":"Szymczyk","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.conctc.2026.101683_bib17","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1210\/jc.2018-02253","article-title":"Medroxyprogesterone acetate in gender-affirming therapy for transwomen: results from a retrospective study","volume":"104","author":"Jain","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.conctc.2026.101683_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13697137.2017.1421925","article-title":"The impact of micronized progesterone on breast cancer risk: a systematic review","volume":"21","author":"Stute","year":"2018","journal-title":"Climacteric"},{"key":"10.1016\/j.conctc.2026.101683_bib19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40360-023-00724-4","article-title":"Addition of progesterone to feminizing gender-affirming hormone therapy in transgender individuals for breast development: a randomized controlled trial","volume":"24","author":"Dijkman","year":"2023","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.conctc.2026.101683_bib20","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1210\/jc.2018-01777","article-title":"Progesterone is important for transgender women's therapy\u2014applying evidence for the benefits of progesterone in ciswomen","volume":"104","author":"Prior","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865426000906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865426000906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T15:49:45Z","timestamp":1792943385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865426000906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":19,"alternative-id":["S2451865426000906"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2026.101683","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progesterone in feminizing gender affirming hormone therapy: study protocol for a randomized placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2026.101683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101683"}}